Recent Updates
Recently added Catalysts
ORIC Positive Sentiment

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

Tuesday, April 25, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ORIC Pharmaceuticals, a clinical stage oncology company, announced its participation in the H.C. Wainwright BioConnect Investor Conference scheduled for May 2, 2023. The event will feature a live webcast of a fireside chat with company management, which aims to enhance investor engagement. The discussion will be accessible through their website, with a replay available for 90 days post-event. This step reflects the company’s strategy to foster communication and interest among investors.
Price reaction · baseline $5.38 (2023-04-24 close) · hit after-hours · clean, no other ORIC news in the window
day 0 close · peak
-6.9%
day 1
-6%
day 3
-3.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • ORIC Pharmaceuticals is engaging with investors, highlighting its commitment to transparency.
  • The firm's focus on therapeutic resistance in oncology is a critical area of research.
  • Participation in the BioConnect Investor Conference may attract further interest and investment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
10.1%
average across 6 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
ORIC-944
Phase 1 · Metastatic Prostate Cancer

Full Press Release Details

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.
The live webcast of the discussion will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.

Frequently Asked Questions

When will ORIC Pharmaceuticals participate in the investor conference?

ORIC Pharmaceuticals will participate in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023.

How can I access the live webcast of the fireside chat?

The live webcast can be accessed through the investor section of ORIC's website.

Is there a replay available for the webcast?

Yes, a replay of the webcast will be available for 90 days after the event.

Who is the Chief Financial Officer of ORIC Pharmaceuticals?

Dominic Piscitelli is the Chief Financial Officer of ORIC Pharmaceuticals.

What is the focus of ORIC Pharmaceuticals?

ORIC Pharmaceuticals focuses on developing treatments for therapeutic resistance in oncology.

ShareAdd on Google
Tags: ORIC Viatris Investor Conferences Healthcare ORIC Pharmaceuticals H.C. Wainwright BioConnect oncology investor engagement
Last updated: Apr 25, 2023

Biotech snapshot

Cash runway
$388M liquidity · $11M/mo burn
~36 mo
Minimal dilution risk
Lead asset
ORIC-944Phase 1
Metastatic Prostate Cancer →

Catalyst track record

+58%
best trade around ORIC's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ORIC.

See every catalyst's timing & PoA →